Effects of para–toluenesulfonamide intratumoral injection on non-small cell lung carcinoma with severe central airway obstruction: A multi-center, non-randomized, single-arm, open-label trial

Li, Shi Yue; Li, Qiang; Wei, Guan; Huang, Jiang; Yang, He; Wu, Guo Ming; Jin, Fa; Hu, Chong; Chen, Liangan; Xu, Guo Liang; Liu, Shou Zhi; Wu, Chang Gui; Han, Bai; Xiang, Ying; Zhao, Jianping; Wang, Jie; Zhou, Xin; Li, Hui Ping; Zhong, Nan

doi:10.1016/j.lungcan.2016.05.012

Cited by 18 publications

(21 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Palliative intratumoral injection chemotherapy is clinically used in treating lung cancer guided with bronchoscopic endobronchial ultrasound, 6,7 central airway obstruction caused by lung carcinoma, 8 extremity melanoma, 9 dysphagia caused by carcinoma, 10 malignant biliary obstruction, 11 recurrent head and neck squamous cell carcinoma, 5,12,13 and midcervical carcinoma. 14 In recent years, several intratumoral delivery systems have been developed that are mainly based on polymers and involve hydrogels, [15][16][17][18] microparticles, 13,19 nanoparticles, 20 nanofibers, 21 etc.…”

Section: Introductionmentioning

confidence: 99%

<p>Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin–chitosan nanoparticles loading paclitaxel–cholesterol complex</p>

Chu¹,

Huang

Wang³

et al. 2019

IJN

View full text Add to dashboard Cite

BackgroundIntratumoral injection is a palliative treatment that aims at further improvement in the survival and quality of life of patients with advanced or recurrent carcinomas, or cancer patients with severe comorbidities or those with a poor performance status.MethodsIn this study, a solvent-injection method was used to prepare paclitaxel–cholesterol complex-loaded lecithin–chitosan nanoparticles (PTX-CH-loaded LCS_NPs) for intratumoral injection therapy, and the physicochemical properties of NPs were well characterized.ResultsThe particle size and zeta potential of PTX-CH-loaded LCS_NPs were 142.83±0.25 nm and 13.50±0.20 mV, respectively. Release behavior of PTX from PTX-CH-loaded LCS_NPs showed a pH-sensitive pattern. The result of cell uptake assay showed that PTX-CH-loaded LCS_NPs could effectively enter cells via the energy-dependent caveolae-mediated endocytosis and macropinocytosis in company with the Golgi apparatus. Meanwhile, PTX-CH-loaded LCS_NPs had a better ability to induce cell apoptosis than PTX solution. The in vivo antitumor results suggested that PTX-CH-loaded LCS_NPs effectively inhibited mouse mammary cancer growth and metastasis to distant organs and significantly improved the survival rate of tumor-bearing mice by intratumoral administration.ConclusionIn general, our study demonstrated that PTX-CH-loaded LCS_NPs used for palliative treatment by intratumoral injection showed improved safety and antitumor efficacy, which provided an alternative approach in the field of palliative chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin–chitosan nanoparticles loading paclitaxel–cholesterol complex</p>

Chu¹,

Huang

Wang³

et al. 2019

IJN

View full text Add to dashboard Cite

show abstract

“…Aside from the longer survival in patients with ACC-SMAO, we also compared the response rate of ACC-SMAO and other patients with non-small cell lung cancer in our previously published study (5). The airway ORR of patients with ACC-SMAO and other patients with lung cancer was 75.0% and 50.8% (chi-square: 1.66, P=0.20), respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, this study has extended from the previous study by specifically analyzing the survival of patients with surgically inoperable ACC-SMAO (5).…”

Section: Methodsmentioning

confidence: 99%

“…The methodology of PTS intratumoral injection has been described previously (5). Before injection, 5 mL PTS (Lot No.…”

Section: Methodsmentioning

confidence: 99%

“…We hypothesized that PTS intratumoral injection would be equally, if not more, effective for ACC-SMAO. Here, we specifically analyzed the effects of PTS intratumoral injection in patients with ACC-SMAO by extending follow-up to 5 years (5).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of para-toluenesulfonamide intratumoral injection on pulmonary adenoid cystic carcinoma complicating with severe central airway obstruction: a 5-year follow-up study

Guan

Zhong

2018

J. Thorac. Dis.

Self Cite

View full text Add to dashboard Cite

Pulmonary adenoid cystic carcinoma (ACC) is a rare type of non-small cell lung carcinoma that may develop life-threatening severe malignant airway obstruction (SMAO). Currently, limited therapeutic approaches exist for ACC-SMAO. We investigated the efficacy and safety of para-toluenesulfonamide (PTS) intratumoral injection for ACC-SMAO. In this phase III, multicenter, non-randomized, single-arm, openlabel trial, we recruited eight hospitalized patients with ACC-SMAO between October 2009 and January 2011. Within the first year, patients received PTS injection for 2-3 sessions weekly, with 2 weeks as a single course. Pre-and post-treatment assessments, including vital sign assessment, dyspnea index, chest computed tomography (CT), were performed shortly before PTS injection and at day 30 post-treatment. We extended the observation to 5 years to determine overall survival. The primary endpoint was the CT-assessed airway objective response rate (ORR) at day 30. The key secondary endpoint was the overall survival (OS) at 5 years post-treatment. At baseline, mean airway tumor cross-sectional area was 153.3 mm 2 (n=8), and the mean airway obstruction rate was 86.1%. The airway ORR reached 100% (33.3% complete remission and 66.7% partial remission). PTS treatment reduced the airway tumor size from 158.2 to 22.7 mm 2 and the average airway obstruction rate decreased from 83.1% to 14.4% (n=6). The 5-year overall survival rate was 50.0%. Median survival duration was 4.98 years (range, 1.39-5.00 years). Four patients (50.0%) had stable disease. Compared with baseline dyspnea index, the transitional dyspnea index increased significantly at 30 days after treatment (mean difference: 5.40; 95% CI, 0.31-10.49; P<0.05). Adverse events were reported in 75% of patients (n=6), of whom 33.3% (n=2) and 66.7% (n=4) were rated as mild and moderate, respectively. No SAE was reported. In conclusion, PTS could rapidly debulk ACC-SMAO, resulting in considerable improvement of five-year survival rate.

show abstract

Overcoming Solubility Challenges: Liposomal isoCoQ‐Carbazole as a Promising Anti‐Tumor Agent for Inoperable and Radiation‐Insensitive cancers

Lamaa,

Cailleau,

Vergnaud

et al. 2024

ChemBioChem

View full text Add to dashboard Cite

This study evaluated the potential of isoCoQ‐Carbazole, a diheterocyclic analog of isoCA‐4, as an anti‐tumor agent. To overcome its low aqueous solubility, liposomes were developed as a delivery system for the compound. In vitro experiments showed that loaded liposomes exhibited similar activity to the free form on multiple human tumor cell lines. In vivo experiments using a palliative intratumoral injection chemotherapy approach further demonstrated that isoCoQ‐Carbazole loaded liposomes significantly reduced tumor growth in a CA‐4‐resistant HT29 cell model, without inducing any observable toxicity or weight loss in the treated mice. These findings suggest that liposomal isoCoQ‐Carbazole may hold promise as a potential therapeutic agent for the treatment of inoperable, radiation‐insensitive cancers.

show abstract

Effects of para–toluenesulfonamide intratumoral injection on non-small cell lung carcinoma with severe central airway obstruction: A multi-center, non-randomized, single-arm, open-label trial

Cited by 18 publications

References 23 publications

<p>Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin–chitosan nanoparticles loading paclitaxel–cholesterol complex</p>

<p>Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin–chitosan nanoparticles loading paclitaxel–cholesterol complex</p>

Effects of para-toluenesulfonamide intratumoral injection on pulmonary adenoid cystic carcinoma complicating with severe central airway obstruction: a 5-year follow-up study

Overcoming Solubility Challenges: Liposomal isoCoQ‐Carbazole as a Promising Anti‐Tumor Agent for Inoperable and Radiation‐Insensitive cancers

Contact Info

Product

Resources

About

Effects of para–toluenesulfonamide intratumoral injection on non-small cell lung carcinoma with severe central airway obstruction: A multi-center, non-randomized, single-arm, open-label trial

Cited by 18 publications

References 23 publications

<p>Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin&ndash;chitosan nanoparticles loading paclitaxel&ndash;cholesterol complex</p>

<p>Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin&ndash;chitosan nanoparticles loading paclitaxel&ndash;cholesterol complex</p>

Effects of para-toluenesulfonamide intratumoral injection on pulmonary adenoid cystic carcinoma complicating with severe central airway obstruction: a 5-year follow-up study

Overcoming Solubility Challenges: Liposomal isoCoQ‐Carbazole as a Promising Anti‐Tumor Agent for Inoperable and Radiation‐Insensitive cancers

Contact Info

Product

Resources

About

<p>Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin–chitosan nanoparticles loading paclitaxel–cholesterol complex</p>

<p>Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin–chitosan nanoparticles loading paclitaxel–cholesterol complex</p>